NCT06793488 Anxiety During Abstinence in AUD
| NCT ID | NCT06793488 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Columbia University |
| Condition | Alcohol Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-09-15 |
| Primary Completion | 2029-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 60 participants in total. It began in 2025-09-15 with a primary completion date of 2029-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to better understand the underlying neurobiological basis of anxiety that emerges during abstinence in patients with alcohol use disorder (AUD). The main questions it aims to answer are: 1. To characterize anxiety itself as well as anxiety related-neurobiological circuitry in early abstinence in AUD 2. To examine how anxiety and anxiety related-neurobiological circuitry change over the course of abstinence in AUD Researchers will recruit both participants with AUD and healthy volunteers. The participants with AUD will be prescribed disulfiram, a medication that helps participants with AUD stay abstinent. Healthy volunteers will not receive antabuse. Patients with AUD will undergo fMRI scanning both after 1 week and 3 months of disulfiram treatment. Healthy volunteers will undergo fMRI once.
Eligibility Criteria
Inclusion Criteria (Participants with Alcohol use Disorder): 1. Between the ages of 21 and 55 2. Right-handed 3. Able to perform informed consent and comply with study 4. Seeking treatment for AUD 5. Meets The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for AUD of at least moderate severity (\>3 symptoms) Inclusion Criteria (Healthy Volunteer Participants): 1. Between the ages of 21 and 55 2. Right-handed 3. Able to perform informed consent and comply with study 4. Report drinking an average of fewer than 8/15 standard drinks per week for women/men and no more than 1 HDD (heavy drinking days) during the previous 28 days. Exclusion Criteria (Participants with Alcohol use Disorder): 1. Neurological, medical or other conditions that would interfere with MRI scanning (e.g., history of stroke, seizure, brain tumor, brain infection, traumatic brain injury, multiple sclerosis, dementia, non MRI-compliant metal device in body, pregnancy, claustrophobia, color blindness, severe hearing impairment, weight\>300 lbs., wheelchair-bound, tattoos as indicated by the guidelines established by the Zuckerman Institute MRI unit: https://mr.research.columbia.edu/ 2. DSM 5 diagnoses of schizophrenia, schizoaffective disorder, or bipolar disorder 3. Any non-AUD psychiatric disorder that may, according to the investigator's judgment, require treatment over the course of the study 4. Significant suicide or violence risk 5. Currently taking psychotropic medication 6. Current substance use disorder other than AUD, tobacco use disorder or mild cannabis use disorder 7. Currently pregnant, attempting to become pregnant or nursing 8. Sufficiently socially unstable as to preclude participation (e.g. homeless). 9. Known history of allergy, intolerance, or hypersensitivity to disulfiram or its derivates 10. Contraindications to disulfiram treatment (e.g. liver disease, kidney disease, cardiac disease, seizure disorder, hypothyroidism, diabetes mellitus, pregnancy or lactation, allergy to disulfiram or thiuram derivatives) 11. Currently taking medications containing alcohol, metronidazole, isoniazid, paraldehyde, phenytoin, warfarin, or theophylline. 12. Treatment with concomitant medications that might interfere with disulfiram 13. A history of alcohol withdrawal seizures, delirium tremens or resistant alcohol withdrawal 14. Current moderate or severe alcohol withdrawal (CIWA \>9 with BAL\<0.05) 15. History of prior disulfiram treatment failure 16. Being abstinent for \> 7 days at the time of screening Exclusion Criteria (Healthy Volunteer Participants): 1. Neurological, medical or other conditions that would interfere with MRI scanning (e.g., history of stroke, seizure, brain tumor, brain infection, traumatic brain injury, multiple sclerosis, dementia, non MRI-compliant metal device in body, pregnancy, claustrophobia, color blindness, severe hearing impairment, weight\>300 lbs., wheelchair- bound, tattoos as indicated by the guidelines established by the ZI MRI unit: https://mr.research.columbia.edu/ 2. DSM 5 diagnoses of schizophrenia, schizoaffective disorder, or bipolar disorder 3. Any psychiatric disorder that may, according to the investigator's judgment, require treatment over the course of the study 4. Significant suicide or violence risk 5. Currently taking psychotropic medication 6. Current substance use disorder other than tobacco use disorder or mild cannabis use disorder 7. Currently pregnant, attempting to become pregnant or nursing 8. Sufficiently socially unstable as to preclude participation (e.g., homeless). 9. A diagnosis of AUD of any severity
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06793488 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 55 Years, studying Alcohol Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06793488 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06793488 currently recruiting?
Yes, NCT06793488 is actively recruiting participants. Contact the research team at abs2257@cumc.columbia.edu for enrollment information.
Where is the NCT06793488 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06793488 clinical trial?
NCT06793488 is sponsored by Columbia University. The trial plans to enroll 60 participants.